Mercey; Guillaume Jean Maurice

Patent Applications and Registrations

Patent applications and USPTO patent grants for Mercey; Guillaume Jean Maurice.The latest application filed is for "further heteroaromatic compounds having activity against rsv".

Company Profile

8.9.10

Mercey; Guillaume Jean Maurice - Issy-les-Moulineaux FR
Mercey; Guillaume Jean Maurice - Montaure FR
Mercey; Guillaume Jean Maurice - Issy-les-Moulineaux Cedex 9 FR
Mercey; Guillaume Jean Maurice - Issy-les Moulirseaux Cedex 9 FR

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Substituted indoline derivatives as dengue viral replication inhibitors Grant 11,407,715 - Bonfanti , et al. August 9, 2	2022-08-09
Pyrazolopyrimidines having activity against the respiratory syncytial virus (RSV) Grant 11,339,165 - Lancois , et al. May 24, 2	2022-05-24
Macrocyclic flu endonuclease inhibitors Grant 11,312,727 - Hendricks , et al. April 26, 2	2022-04-26
Further Heteroaromatic Compounds Having Activity Against Rsv App 20220033396 - GUILLEMONT; Jerome Emile Georges ; et al.	2022-02-03
Aryl substituted pyrimidines for use in influenza virus infection Grant 11,117,887 - Jonckers , et al. September 14, 2	2021-09-14
Bicyclic pyridine, pyrazine, and pyrimidine derivatives as PI3K beta inhibitors Grant 10,894,793 - Berthelot , et al. January 19, 2	2021-01-19
Pyrazolopyrimidines Having Activity Against The Respiratory Syncytial Virus (rsv) App 20200361942 - LAN OIS; David Francis Alain ; et al.	2020-11-19
Substituted Indoline Derivatives As Dengue Viral Replication Inhibitors App 20200255376 - Kind Code	2020-08-13
Aryl Substituted Pyrimidines For Use Influenza Virus Infection App 20200231577 - JONCKERS; Tim Hugo Maria ; et al.	2020-07-23
Aryl substituted pyrimidines for use in influenza virus infection Grant 10,611,755 - Jonckers , et al.	2020-04-07
Azabenzimidazole Derivatives As Pi3k Beta Inhibitors App 20190263804 - Pilatte; Isabelle Noelle Constance ; et al.	2019-08-29
Bicyclic Pyridine, Pyrazine, And Pyrimidine Derivatives As Pi3k Beta Inhibitors App 20190169199 - Berthelot; Didier Jean-Claude ; et al.	2019-06-06
Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as Ros1 inhibitors Grant 10,280,170 - Mevellec , et al.	2019-05-07
Aryl Substituted Pyrimidines For Use In Influenza Virus Infection App 20190047989 - JONCKERS; Tim Hugo Maria ; et al.	2019-02-14
Heterocyclyl linked imidazopyridazine derivatives as PI3KB inhibitors Grant 10,202,387 - Mevellec , et al. Feb	2019-02-12
Imidazopyridazine derivatives as PI3KB inhibitors Grant 10,087,187 - Mevellec , et al. October 2, 2	2018-10-02
Heterocyclyl Linked Imidazopyridazine Derivatives As Pi3kb Inhibitors App 20180057496 - Mevellec; Laurence Anne ; et al.	2018-03-01
Imidazopyridazine Derivatives As Pi3kb Inhibitors App 20180002336 - Mevellec; Laurence Anne ; et al.	2018-01-04
SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS App 20170174690 - Mevellec; Laurence Anne ; et al.	2017-06-22

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.